Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The onset of the therapeutic response to antidepressant treatment exhibits a characteristic delay. Animal models sensitive to chronic, but not acute, antidepressant treatment are greatly needed for studying antidepressant mechanisms. We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders. Only the highly anxious BALB/c strain exhibited sensitivity to fluoxetine in the forced swim test. Additionally, fluoxetine reduced locomotion in C57BL/6 and 129SvEv, but not BALB/c and DBA/2, strains. We then evaluated the effects of subchronic (approximately 4 days) and chronic (approximately 24 days) fluoxetine treatment (0, 10, 18, 25 mg/kg/day) on measures of anxiety and depression in BALB/c mice. Anxiety measures were obtained using the open field and novelty-induced hypophagia tests. Antidepressant effects were evaluated using the forced swim test. We found 18 mg/kg/day of chronic fluoxetine to be active in all three paradigms; subchronic treatment had no effect. Anxiety-related measures were reduced by 18 mg/kg/day. In the forced swim test, 10 and 18 mg/kg/day increased swimming and reduced immobility. Here we present several novel effects of chronic, but not subchronic, antidepressant treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dosage of 18 mg/kg/day have been shown to be in the upper range of the therapeutic dose of fluoxetine administered to humans.16”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [16]
In the citing paper
“Hyponeophagia (novelty-suppressed feeding) has also been used to assess anxiety-like behavior in rodents; in a novel environment, hungry mice exhibit an increased latency to feed that is sensitive to benzodiazepines and SSRIs47,48.”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [47]
In the citing paper
“The NIH paradigm is a sensitive measure for potential anxiolytic drugs and anxiogenic effects of withdrawal on both acute and extended drug administration paradigms (Dulawa et al., 2004;Dulawa and Hen, 2005).”
From Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors (2014) · cites this paper as Dulawa et al., 2004
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“We have previously shown that steady state for both fluoxetine and norfluoxetine is achieved by 5 days of receiving fluoxetine in the drinking water (10 mgskgsday), as serum levels after 5 or 90 days of treatment are equivalent (”
BackgroundSelf-citationBehavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,013
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review
Prut, L., & Belzung, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01272-x · Cited by 3,175
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“The intake of palatable fluids, including sucrose and saccharin solutions, has been used as a measure of reward sensitivity (”
MethodAssessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551
Psychopharmacology: The Fourth Generation of Progress
Green, A. I. (1996) · Psychiatric Services · doi:10.1176/ps.47.3.312 · Cited by 1,145
Neuropsychopharmacology: The Fifth Generation of Progress
SAGDUYU, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,019
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Antidepressants and neuroplasticity
D'Sa, C., & Duman, R. S. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01203.x · Cited by 513 · cited 1×
“These long-term effects are thought to involve increases in neural plasticity and growth-related events (”
Background
Research works printed but not linked: 2
- Hirschfeld R, Weisssman M (2002). Risk factors for major depression and bipolar disorder. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 1018–1025.
- Merikangas K, Pine D (2002). Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 868–882.
Cited by
Items 201–300 of 693
Sun, Y., Zupan, B., Raaka, B. M., Tóth, M., & Gershengorn, M. C. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.217 · Cited by 56
“Three cohorts were tested in the following order: Cohort 1, (i) EPM, (ii) OF, (iii) LA, (iv) PPI, (v) FST; Cohorts 2 and 3, (i) FST, (ii) TST, (iii) NIHT.”
MethodInfluentialWarden, S. J., & Haney, E. M. (2008) · PubMed · Cited by 60
The Role of Serotonin, Vasopressin, and Serotonin/Vasopressin Interactions in Aggressive Behavior
Morrison, T. R., & Melloni, R. H. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_283 · Cited by 57
“…periods have shown that both depressive and anxiety-related behaviors, which are reduced by late-life exposure to SSRIs in highly anxious mice (Dulawa et al. 2004), may be either increased or decreased by fluoxetine exposure early in life (Ansorge et al. 2008; Ansorge et al. 2004; Maciag et…”
BackgroundRantamäki, T., Knuuttila, J. E. A., Hokkanen, M., & Ċastrén, E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.001 · Cited by 63
“This mouse strain is particularly relevant in experiments addressing the effects of moodaltering drugs since they are highly emotional and responsive to the behavioural effects of antidepressants (Ducottet et al., 2003; Dulawa et al., 2004; Englander et al., 2005).”
BackgroundThoeringer, C. K., Erhardt, A., Sillaber, I., Mueller, M., Ohl, F., Holsboer, F., & Keck, M. E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103091 · Cited by 59
Characterization of 5-HT1A/1B−/− mice: An animal model sensitive to anxiolytic treatments
Guilloux, J., David, D. J. P., Xia, L., Nguyen, H. T., Rainer, Q., Guiard, B. P., Repérant, C., Deltheil, T., Tóth, M., Hen, R., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.009 · Cited by 54
“Similarly, SSRIs are effective in animal models of high anxious-like states, but not in controls or in non-anxious strains ofmice (David et al., 2009; Dulawa et al., 2004).”
BackgroundSelf-citationYun, S., Donovan, M. H., Ross, M. N., Richardson, D. R., Reister, R., Farnbauch, L. A., Fischer, S. J., Riethmacher, D., Gershenfeld, H. K., Lagace, D. C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147256 · Cited by 49
“This test has excellent pharmacologic and ethological validation [30, 66], does not involve overnight food restriction, and minimizes food neophobia via the repeated exposure to the highly palatable food in a familiar cage.”
BackgroundHou, X.-Y., Hu, Z., Zhang, D.-Z., Lu, W., Zhou, J., Wu, P.-F., Guan, X., Han, Q.-Q., Deng, S., Zhang, H., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6737 · Cited by 54
Perić, I., Stanisavljević, A., Gass, P., & Filipović, D. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0807-9 · Cited by 54
“1 3 human patients treated with therapeutically effective doses of 20–80 mg/day Prozac (100–700 ng/ml) [28].”
BackgroundAssessing the validity of current mouse genetic models of obsessive-compulsive disorder
Wang, L., Simpson, H. B., & Dulawa, S. C. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a80ad · Cited by 50
“Two, the dose of fluoxetine used (5λmg/kg/day) is substantially lower than doses typically found to reduce anxiety and depression-related behavior in mice in chronic models (Dulawa et al., 2004; Shanahan et al., 2008; Yalcin et al., 2008) (10–20λmg/ kg/day), and higher doses of SRIs are typically required to treat OCD…”
BackgroundInfluentialSelf-citationBen‐Azu, B., Adebayo, O. G., Moke, E. G., Omogbiya, A. I., Oritsemuelebi, B., Chidebe, E. O., Umukoro, E. K., Nwangwa, E. K., Etijoro, E., Umukoro, E. K., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.10.057 · Cited by 54
Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids
Gunduz-Cinar, O., Flynn, S., Brockway, E., Kaugars, K., Baldi, R., Ramikie, T. S., Cinar, R., Kunos, G., Patel, S., & Holmes, A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.318 · Cited by 47
Danio rerio embryos on Prozac Effects on the detoxification mechanism and embryo development
Cunha, V. F. P. M., Rodrigues, P., Santos, M. M., Moradas‐Ferreira, P., & Ferreira, M. (2016) · Aquatic Toxicology · doi:10.1016/j.aquatox.2016.08.003 · Cited by 52
Corbett, B. F., Luz, S., Arner, J., Pearson-Leary, J., Sengupta, A., Taylor, D. M., Gehrman, P., Ross, R. J. M., & Bhatnagar, S. (2019) · Nature Communications · doi:10.1038/s41467-019-10904-8 · Cited by 58
Faye, C., Hen, R., Guiard, B. P., Denny, C. A., Gardier, A. M., Mendez‐David, I., & David, D. J. P. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.08.009 · Cited by 54
Self-citationD’Andrea, I., Gracci, F., Alleva, E., & Branchi, I. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.06.030 · Cited by 54
Corticotropin-releasing factor type-1 receptor antagonists: The next class of antidepressants?
Nielsen, D. M. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.06.003 · Cited by 54
“Likewise, in the mouse forced swim test the ability to detect antidepressant-like activity with fluoxetine is enhanced when a chronic dosing paradigm is used (Dulawa et al., 2004).”
BackgroundKryst, J., Majcher‐Maślanka, I., & Chocyk, A. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00420-w · Cited by 54
“Another limitation is that our findings should be considered as relating mostly to Wistar rats, while as reported previously, the antidepressant-like effects of fluoxetine in the FST might be straindependent [121, 161].”
BackgroundResultBechtholt, A. J., Smith, K. L., John, C. S., Kang, H., Carlezon, W. A., Cohen, B. M., & Öngür, D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2169-8 · Cited by 51
“Next, we examined the short- and long-term effects of ketamine in the TST with doses ranging from 40 to 320 mg/kg in Balb/cJ mice, a strain that is reportedly vulnerable to depressive-like symptoms (Belzung and Griebel 2001; Dulawa et al. 2004; Popa et al. 2008; 2010; Trullas et al. 1989) and is particularly sensitive…”
BackgroundInfluentialNorden, D. M., Devine, R., Bicer, S., Jing, R., Reiser, P. J., Wold, L. E., Godbout, J. P., & McCarthy, D. O. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.12.045 · Cited by 48
Chen, W., Xie, B., Zhang, C., Xu, K.-L., Niu, Y., Tang, X., Zhang, P., Zou, W., Hu, B., & Tian, Y. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283654258 · Cited by 50
“, 2011) and evidence that antidepressants are efficacious not only against depression but also in the treatment of anxiety disorders (Sonawalla et al., 2002; Gorman, 2003; Dulawa et al., 2004) suggest that depression and anxiety might share common genetic etiology and neural substrates (Gorwood, 2004; Kim et al.”
BackgroundRobert, G., Drapier, D., Bentué‐Ferrer, D., Renault, A., & Reymann, J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.051 · Cited by 49
Wang, G., Cheng, Y., Gong, M., Liang, B., Zhang, M., Chen, Y., Zhang, C., Yuan, X., & Xu, J. (2013) · Neuroreport · doi:10.1097/wnr.0b013e32836384db · Cited by 53
The antidepressant-like effect of tDCS in mice: A behavioral and neurobiological characterization
Peanlikhit, T., Waes, V. V., Pédron, S., Risold, P., Haffen, É., Etiévant, A., & Monnin, J. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.03.012 · Cited by 50
Majeed, A., Xiong, J., Teopiz, K. M., Ng, J., Ho, R., Rosenblat, J. D., Phan, L., Cao, B., & McIntyre, R. S. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1898588 · Cited by 48
“SSRIs) have been shown to decrease the latency to feed in NIH [32,41].”
BackgroundInfluentialAnxiolytic effect of serotonin depletion in the novelty-induced hypophagia test
Bechtholt, A. J., Hill, T. E., & Lucki, I. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0615-9 · Cited by 48
“1988) test, that minimizes secondary motivational and feeding effects by omitting food deprivation and including home cage assessments (Dulawa and Hen 2005; Dulawa et al. 2004; Merali et al. 2003, 2004).”
BackgroundInfluentialVascular growth factors in neuropsychiatry
Newton, S. S., Fournier, N. M., & Duman, R. S. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1281-9 · Cited by 48
“The effect was comparable to that obtained by chronic treatment (3 weeks) with SSRI antidepressants [125].”
ResultThe inflammatory response to social defeat is increased in older mice
Kinsey, S. G., Bailey, M. T., Sheridan, J. F., & Padgett, D. A. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.003 · Cited by 48
“These effects can be reversed by anxiolytic compounds [26–30].”
BackgroundRebai, R., Jasmin, L., & Boudah, A. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.07.013 · Cited by 50
Badr, A. M., Attia, H., & Al-Rasheed, N. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60026-1 · Cited by 53
Guzzetti, S., Calcagno, E., Canetta, A., Sacchetti, G., Fracasso, C., Caccia, S., Cervo, L., & Invernizzi, R. W. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.031 · Cited by 49
“Indeed, an increase in swimming and a nonsignificant reduction in immobility time was found in BALB/c mice given fluoxetine for 24 days (Dulawa et al., 2004).”
BackgroundAntidepressants: Influence on cancer and immunity?
Frick, L. R., & Rapanelli, M. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.020 · Cited by 50
“Oral administration of 10–25 mg/kg fluoxetine in mice results in plasma concentrations of approximately 170–1780 ng/ml, which correspond to 5×10−7 M−5×10−6 M (Dulawa et al., 2004).”
BackgroundThakker-Varia, S., Jean, Y. Y., Parikh, P., Sizer, C. F., Jernstedt Ayer, J., Parikh, A., Hyde, T. M., Buyske, S., & Alder, J. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5987-09.2010 · Cited by 46
“…treatment To elaborate the role of VGF in bipolar disorder, we used a behavioral procedure, novelty-induced hypophagia, which is only sensitive to the effects of chronic, but not acute or subchronic, antidepressant treatment (Dulawa et al., 2004; Cryan and Holmes, 2005; Dulawa and Hen, 2005).”
MethodThe Antidepressant Effect ofGastrodia elataBl. on the Forced-Swimming Test in Rats
Chen, P., Hsieh, C., Su, K., Hou, Y., Chiang, H., Lin, I.-H., & Sheen, L. (2008) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x08005618 · Cited by 47
Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse
Razzoli, M., Carboni, L., Andreoli, M., Michielin, F., Ballottari, A., & Arban, R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.09.010 · Cited by 46
“, 2001) and chronic drug treatments (Dulawa et al., 2004; Holick et al., 2008).”
InfluentialMitić, M., Simic, I., Djordjevic, J., Radojcic, M. B., & Adžić, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.012 · Cited by 49
Xia, B., Chen, C., Zhang, H., Xue, W., Tang, J., Tao, W., Wu, R., Ren, L., Wang, W., & Chen, G. (2016) · Scientific Reports · doi:10.1038/srep35042 · Cited by 49
Identification of a novel, fast-acting GABAergic antidepressant
McMurray, K. M. J., Ramaker, M. J., Barkley-Levenson, A. M., Sidhu, P. S., Elkin, P. K., Reddy, M. K., Guthrie, M. L., Cook, J. M., Rawal, V. H., Arnold, L. A., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.14 · Cited by 50
Self-citationPopova, D., Ċastrén, E., & Taira, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.003 · Cited by 50
“It has been previously reported that the protocol results in FLX plasma levels corresponding therapeutic range in humans (Dulawa et al., 2004).”
InfluentialAP-1 controls the p11-dependent antidepressant response
Chottekalapanda, R. U., Kalik, S., Gresack, J. E., Ayala, A., Gao, M., Wang, W., Meller, S. J., Aly, A., Schaefer, A., & Greengard, P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0767-8 · Cited by 49
Filipović, D., Costina, V., Perić, I., Stanisavljević, A., & Findeisen, P. (2017) · Brain Research · doi:10.1016/j.brainres.2017.01.025 · Cited by 46
“…resulted in a mean (±SEM) serum concentration of 280 ± 50 ng/ml in Flx-treated rats 24 h following the last treatment (Zlatković et al., 2014), similar to those reported in human patients treated with therapeutically effective doses of 20-80 mg/day Prozac (100-700 ng/ml) (Dulawa et al., 2004).”
Song, T., Wu, H., Li, R., Xu, H., Rao, X., Gao, L., Zou, Y., & Lei, H. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.03.009 · Cited by 45
“Even though improved depressionlike behaviors, as assessed by the FST, have been consistently reported in the Flx-treated animals [28,30,31], the previous observations with respect to the Flx-induced behavioral changes in the EPM test, SPT and other cognitive tasks have been less consistent, and sometimes even contrad…”
Savalli, G., Diao, W., Berger, S., Ronovsky, M., Partonen, T., & Pollak, D. D. (2015) · Amino Acids · doi:10.1007/s00726-015-1968-3 · Cited by 46
“…observation in the NSF, however, suggests that Cry2 may be involved in or modulate some of the signaling cascades activated by chronic antidepressant drug treatment which is known to induce a decreased latency to feed in the NSF (Dulawa et al. 2004; Mineur et al. 2009; Warner-Schmidt et al. 2011).”
BackgroundMethodResultAntidepressant response to chronic citalopram treatment in eight inbred mouse strains
Jiao, J., Nitzke, A. M., Doukas, D. G., Seiglie, M. P., & Dulawa, S. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2140-0 · Cited by 46
“We performed the modified FST as described previously (Dulawa et al. 2004; Holick et al. 2008).”
BackgroundMethodInfluentialSelf-citationByeon, E., Park, J. C., Hagiwara, A., Han, J., & Lee, J. (2019) · Aquatic Toxicology · doi:10.1016/j.aquatox.2019.105337 · Cited by 53
Jiao, J., Opal, M. D., & Dulawa, S. C. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.136 · Cited by 47
Self-citationNavailles, S., Zimnisky, R., & Schmauss, C. (2010) · Developmental Neuroscience · doi:10.1159/000293989 · Cited by 41
“This dose has been shown to yield ‘therapeutic’ plasma levels [Dulawa et al., 2004], and we have previously shown significant effects of this dose on behavior and gene expression in mice [Bhansali et al.”
BackgroundCamargo, A., Pazini, F. L., Rosa, J. M., Wolin, I. A. V., Moretti, M., da Rosa, P. B., Neis, V. B., & Rodrigues, A. L. S. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.017 · Cited by 45
Doron, R., Lotan, D., Versano, Z., Benatav, L., Franko, M., Armoza, S., Kately, N., & Rehavi, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091455 · Cited by 42
“It has been repeatedly shown that SSRIs can reduce anxiety symptoms in patients suffering from anxiety disorders [4,35,36], and anxietylike behaviors in animal studies [37,38].”
BackgroundBehavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine
Kobayashi, K., Ikeda, Y., & Suzuki, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-12 · Cited by 41
“Since the destabilization of mouse behaviors were observed at the dose higher than the clinical therapeutic dose of fluoxetine and suggested optimal dose for mice [22], this effect may not be directly relevant to clinical symptoms or behavioral changes in humans.”
BackgroundSu, J., Chen, J., Lippold, K., Monavarfeshani, A., Carrillo, G. L., Jenkins, R., & Fox, M. A. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201509085 · Cited by 45
Дыгало, Н. Н., Shishkina, G. T., Kalinina, T. S., Yudina, A., & Ovchinnikova, E. S. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.08.004 · Cited by 51
Lee, H., Rao, J. S., Ertley, R. N., Chang, L., Rapoport, S. I., & Bazinet, R. P. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0582-1 · Cited by 42
“This dosing regimen decreases depression scores in rodents, as measured by a variety of behavioral and biochemical tests (De Foubert et al. 2004; Dulawa et al. 2004; El Yacoubi et al. 2003).”
RetractedBrookshire, B. R., & Jones, S. R. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.008 · Cited by 42
“It has been generally agreed that fluoxetine produces decreases in locomotor activity at high doses (Pessia et al., 1994;Dulawa et al., 2004), but as yet, no studies have been performed analyzing the effect of sex on locomotor activity following fluoxetine administration.”
BackgroundFrick, L. R., Rapanelli, M., Cremaschi, G., & Genaro, A. M. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.06.010 · Cited by 46
Hyperactivity of indirect pathway-projecting spiny projection neurons promotes compulsive behavior
Piantadosi, S. C., Manning, E. E., Chamberlain, B. L., Hyde, J., LaPalombara, Z., Bannon, N. M., Pierson, J. L., Namboodiri, V. M. K., & Ahmari, S. E. (2024) · Nature Communications · doi:10.1038/s41467-024-48331-z · Cited by 43
Modeling PTSD in the zebrafish: Are we there yet?
Caramillo, E. M., Khan, K. M., Collier, A. D., & Echevarria, D. J. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.005 · Cited by 45
Haj‐Mirzaian, A., Kordjazy, N., Ostadhadi, S., Amiri, S., Haj‐Mirzaian, A., & Dehpour, A. R. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0429 · Cited by 43
“2005), and fluoxetine (a SSRI) (Dulawa et al. 2004) were administered 30 min before the behavioral tests.”
MethodA novel 5HT3 receptor–IGF1 mechanism distinct from SSRI-induced antidepressant effects
Kondo, M., Koyama, Y., Nakamura, Y., & Shimada, S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.87 · Cited by 41
Fibroblast growth factor 2 is necessary for the antidepressant effects of fluoxetine
Simard, S., Shail, P., MacGregor, J., Sayed, M. E., Duman, R. S., Vaccarino, F. M., & Salmaso, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204980 · Cited by 43
“Moreover, previous reports have shown strain differences that are consistent with our results here in C57/Bl6 mice [29].”
ResultZhao, J., Jung, Y.-H., Jin, Y., Kang, S., Jang, C., & Lee, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-44052-2 · Cited by 40
Andreasen, J. T., Gynther, M., Rygaard, A., Bøgelund, T., Nielsen, S. D., Clausen, R. P., Mogensen, J., & Pickering, D. S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.04.045 · Cited by 42
Zhou, L., Ma, S. L., Yeung, P. K. K., Wong, Y. H., Tsim, K. W. K., So, K., LAM, L. C. W., & Chung, S. K. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.129 · Cited by 44
Moderate Maternal Alcohol Exposure on Gestational Day 12 Impacts Anxiety-Like Behavior in Offspring
Rouzer, S., Cole, J., Johnson, J. M., Varlinskaya, E., & Diaz, M. R. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00183 · Cited by 41
Kim, E. J., Kim, W. R., Chi, S. E., Lee, K. H., Park, E., Chae, J., Park, S. K., Kim, H. T., & Choi, J.-S. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.023 · Cited by 44
Bechtholt, A. J., Valentino, R. J., & Lucki, I. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301616 · Cited by 40
“In the NIH test, the anxiety-provoking effects of novelty can be reduced by either acute administration of benzodiazepines or by chronic antidepressants (Dulawa et al, 2004; Merali et al, 2003; Sanders and Shekhar, 1995).”
CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice
Onaka, Y., Shintani, N., Nakazawa, T., Haba, R., Ago, Y., Wang, H., Kanoh, T., Hayata‐Takano, A., Hirai, H., Nagata, K., et al. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.02.013 · Cited by 42
Yang, J., Pei, Y., Pan, Y., Jia, J., Shi, C., Yu, Y., Deng, J., Li, B., Gong, X., Wang, X., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/107380 · Cited by 45
“FST is widely used as a screening procedure for antidepressants [37, 43].”
Nip, E., Adcock, A., Nazal, B., MacLellan, A., Niel, L., Choleris, E., Levison, L., & Mason, G. J. (2019) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2019.05.002 · Cited by 42
Rao, J. S., Ertley, R. N., Lee, H.-J., Rapoport, S. I., & Bazinet, R. P. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500391 · Cited by 41
RetractedDuan, D., Yang, X., Ya, T., & Chen, L. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.125333 · Cited by 39
Malki, K., Mineur, Y. S., Tosto, M. G., Campbell, J., Karia, P., Jumabhoy, I., Sluyter, F., Crusio, W. E., & Schalkwyk, L. C. (2015) · BMC Genomics · doi:10.1186/s12864-015-1431-6 · Cited by 37
“Discussion This study investigated gene expression differences in the context of a GxE model using two contrasting mouse strains, BALB/cJ, a highly stress-reactive, anxious and emotive strain with low basal locomotor activity and C57BL/6, which is considered a less emotive and anxious strain [56-59].”
Ben‐Azu, B., Moke, E. G., Chris-Ozoko, L. E., Jaiyeoba-Ojigho, E. J., Adebayo, O. G., Ajayi, A. M., Oyovwi, M. O., Odjugo, G., Omozojie, V. I., Ejomafuwe, G., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-023-06509-1 · Cited by 40
Chronic Antidepressant Treatment in Normal Mice Induces Anxiety and Impairs Stress-coping Ability
Baek, I., Park, J. Y., & Han, P. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.2.156 · Cited by 44
“dark box test, novelty suppressed feeding test, open field test, and social interaction test [22-25], whereas a number of other studies have reported that chronic antidepressant treatments produce anxiolytic effects [11, 12, 26, 27] or no effect at all [17, 19, 21, 25, 28, 29].”
BackgroundDifferent Views of Anxiety Disorders
Selek, S. (2011) · InTech eBooks · doi:10.5772/1022 · Cited by 39
“, 2009), responses that parallel those seen in rodents (Dulawa et al., 2004).”
BackgroundThe potentially beneficial central nervous system activity profile of ivacaftor and its metabolites
Schneider‐Futschik, E. K., McQuade, R. M., Carbone, V., Reyes‐Ortega, F., Wilson, J. W., Button, B., Saito, A., Poole, D. P., Hoyer, D., Li, J., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00127-2017 · Cited by 39
Chronic Intake of the Selective Serotonin Reuptake Inhibitor Fluoxetine Enhances Atherosclerosis
Rami, M., Guillamat‐Prats, R., Rinne, P., Salvermoser, M., Ring, L., Bianchini, M., Blanchet, X., Megens, R. T. A., Döring, Y., Walzog, B., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310536 · Cited by 42
Millard, S. J., Lum, J. S., Fernandez, F., Weston–Green, K., & Newell, K. A. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822141 · Cited by 41
Zavvari, F., Nahavandi, A., & Goudarzi, M. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.101711 · Cited by 38
Nguyen, H. T., Guiard, B. P., Bacq, A., David, D. J. P., Mendez‐David, I., Quesseveur, G., Gautron, S., Sánchez, C., & Gardier, A. M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01850.x · Cited by 40
“Swimming behaviour relies on the 5-hydroxytryptaminergic system and climbing behaviour on the noradrenergic system in mice (Dulawa et al., 2004; Holick et al., 2008).”
BackgroundAdult vertebrate behavioural aquatic toxicology: Reliability and validity
Parker, M. O. (2015) · Aquatic Toxicology · doi:10.1016/j.aquatox.2015.09.001 · Cited by 41
“Fluoxetine, a selective serotonin reuptake inhibitor SSRI), is known to have efficacy both as an antidepressant and s an anxiolytic agent (Dulawa et al., 2004).”
BackgroundBen‐Azu, B., Oritsemuelebi, B., Oghorodi, A. M., Adebesin, A., Isibor, H., Eduviere, A. T., Otuacha, S. O., Akudo, M., Ekereya, S., Maidoh, I. F., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176791 · Cited by 38
Lee, H.-Y., Joo, J., Nah, S., Kim, J.-W., Kim, H., Kwon, J., LEE, H.-Y., Kim, Y. O., & KIM, H.-J. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2161 · Cited by 39
“…(horizontal movement throughout the chamber and crossing quadrants), climbing behavior (upward-directed movements up the side of the chamber and jump-ups from the bottom of the chamber), and immobility (no additional activity other than keeping the head above water or tiny whip kicks) (30,31).”
InfluentialShah, A. P., Carreno, F. R., Wu, H., Chung, Y. A., & Frazer, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.024 · Cited by 38
“The effects of AD drugs in this test are consistent with their effects in humans, where an anxiolytic response is seen only when the drugs are administered chronically (Bodnoff et al., 1988; Santarelli et al., 2003; Dulawa et al., 2004).”
BackgroundParolini, M., Ghilardi, A., Felice, B. D., & Giacco, L. D. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-06619-4 · Cited by 42
“In addition, FLX induced anxiolytic effects in rodents and fish (Dulawa et al. 2004; Egan et al. 2009).”
BackgroundRayan, N. A., Kumar, V., Aow, J., Rastegar, N., Lim, M. G. L., O’Toole, N., Aliwarga, E., Arcego, D. M., Yeo, G. H. T., Wong, J. Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01725-1 · Cited by 42
“Thus, our fluoxetine treatment of naïve animals successfully reproduced the well-known reduction in behavioural despair induced by antidepressants [39].”
Self-citationThe Role of Serotonin in Depression
Carr, G. V., & Lucki, I. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70098-9 · Cited by 45
Zhao, Y., Lin, Z., Chen, L., Ouyang, L., Gu, L., Chen, F., & Zhang, Q. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.011 · Cited by 40
He, R., Li, Y.-F., Wu, Y., Gao, H., Ouyang, S., & Kurihara, H. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.244792 · Cited by 37
“Even in normal mice, fluoxetine treatment can increase 5-HT levels in the hippocampus (Imoto et al., 2015) and counteract depression-like behaviors in the elevated plus maze and open field test (Silva and Brandao, 2000; Dulawa et al., 2004; Drapier et al., 2007).”
Nashed, M. G., Seidlitz, E. P., Frey, B. N., & Singh, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.040 · Cited by 41
“μg/mL to obtain dosages between 10-‐18 mg/kg/day [23].”
Ostadhadi, S., Haj‐Mirzaian, A., Nikoui, V., Kordjazy, N., & Dehpour, A. R. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12518 · Cited by 38
Yohn, C. N., Shifman, S. G., Garino, A., Diethorn, E. J., Bokka, L., Ashamalla, S. A., & Samuels, B. A. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05456-5 · Cited by 37
Sadegzadeh, F., Sakhaie, N., Dehghany, R., Adak, O., & Saadati, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118338 · Cited by 38
Suryanto, M. E., Audira, G., Uapipatanakul, B., Hussain, A., Saputra, F., Siregar, P., Chen, K. H. ‐., & Hsiao, C. (2021) · Cells · doi:10.3390/cells10040738 · Cited by 37
Ouyang, X., Wang, Z., Luo, M., Wang, M., Liu, X., Chen, J., Feng, J., Jia, J., & Wang, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-97758-7 · Cited by 37
Gupta, D., Radhakrishnan, M., & Kurhe, Y. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.05.024 · Cited by 38
1-Oleoyl Lysophosphatidic Acid: A New Mediator of Emotional Behavior in Rats
Castilla‐Ortega, E., Escuredo, L., Bilbao, A., Pedraza, C., Orío, L., Estivill‐Torrús, G., Santín, L. J., de Fonseca, F. R., & Pavón, F. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085348 · Cited by 40
Topical Fluoxetine as a Novel Therapeutic That Improves Wound Healing in Diabetic Mice
Nguyen, C., Tartar, D. M., Bagood, M. D., So, M., Nguyen, A. V., Gallegos, A., Fregoso, D. R., Serrano, J. I., Nguyen, D., Degovics, D., et al. (2019) · Diabetes · doi:10.2337/db18-1146 · Cited by 40
“The FLX levels measured are twofold lower than plasma levels in patients treated with oral FLX at therapeutic doses and are also significantly lower than levels in mice treated with neurologically therapeutic doses of FLX, either orally or intraperitoneally administered (21,22).”
BackgroundBtbd3 expression regulates compulsive-like and exploratory behaviors in mice
Thompson, S. L., Welch, A. C., Ho, E. V., Bessa, J. M., Portugal‐Nunes, C., Morais, M., Young, J. W., Knowles, J. A., & Dulawa, S. C. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0558-7 · Cited by 36
Self-citationHu, Q., Liu, L., Zhou, L. N., Lu, H., Wang, J., Chen, X., & Wang, Q. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113312 · Cited by 39
Metadata
- Authors
- Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R.
- Affiliations
- Columbia University (US)
- Venue
- Neuropsychopharmacology
- Published
- 2004-04-07
- Volume
- 29
- Issue
- 7
- Pages
- 1321-1330
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1987972424
- Cited by
- 671
- References
- 50
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 28 · 2022: 32 · 2021: 32 · 2020: 31 · 2019: 51 · 2018: 31 · 2017: 42 · 2016: 34 · 2015: 42 · 2014: 41 · 2013: 44 · 2012: 28
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression (MH068542-1)
- National Institutes of Health (5r01da009862-08, 5f32mh065791-02)
- National Institute of Mental Health (F32-MH65791-01A1, P50MH050733, P50-MH50733, R01 MH068542-1, R01MH068542)
- National Institute on Drug Abuse (R01 DA09862)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- fluoxetine, chronic antidepressant treatment, anxiety, depression, selective serotonin reuptake inhibitors, inbred mouse strains, BALB/c mice, forced swim test, novelty-induced hypophagia, locomotor activity, antidepressant sensitivity
- MeSH terms
- Analysis of Variance, Animals, Anxiety, Behavior, Animal, Depression, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Administration Schedule, Exploratory Behavior, Fluoxetine, Immobilization, Male, Mice, Inbred Strains, Motor Activity, Reaction Time, Species Specificity, Swimming, Time Factors, Selective Serotonin Reuptake Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.